GLP-1, or {glucagon-like|glucagon like|glucagon) peptide-1, is rapidly becoming a prominent focus in therapeutic studies, largely due to its notable impact on controlling diseases such as adult-onset diabetes and obesity. Recent trials have demonstrated that beyond glucose control, GLP-1 agonists offer potential for cardiovascular well-being and… Read More